From 61cd78a06afd568d1412e30ee72b2f0fa7204dcf Mon Sep 17 00:00:00 2001 From: OpenWiki Bot Date: Wed, 29 Jul 2026 02:12:55 +0800 Subject: [PATCH] chore: daily update 2026-07-29 --- .last-update.json | 2 +- commitments.md | 7 ++++ open-questions.md | 6 ++- quickstart.md | 8 ++-- sources/git-repo.md | 98 ++++++++++++++++++++++++++++++------------- sources/hackernews.md | 47 +++++++++++++++++++-- sources/web-search.md | 53 ++++++++++++++++++++++- themes.md | 5 ++- 8 files changed, 184 insertions(+), 42 deletions(-) diff --git a/.last-update.json b/.last-update.json index 48a61e9..14d0847 100644 --- a/.last-update.json +++ b/.last-update.json @@ -1,5 +1,5 @@ { - "updatedAt": "2026-07-27T18:10:46.353Z", + "updatedAt": "2026-07-28T18:10:15.764Z", "command": "update", "model": "MiniMax-M3" } diff --git a/commitments.md b/commitments.md index 4484fbe..23bc01a 100644 --- a/commitments.md +++ b/commitments.md @@ -18,6 +18,13 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G - Status: open - Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal. +### china-order-no-818-clinical-translation: verify Order No. 818 (effective 2026-05-01) scope for Chinese pharma / CDMO conversations +- Owner: me +- Source: web-search — BetaLife LinkedIn 2026-07 (top score 0.779; explicitly cites "Order No. 818, effective May 1, 2026" with accelerated clinical-translation pathway); Tavily answer text corroborates; Roots Analysis re-mentions broader China cell-therapy regulatory pattern +- Due: unscheduled +- Status: open +- Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation. +